MX2008010824A - Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro. - Google Patents

Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro.

Info

Publication number
MX2008010824A
MX2008010824A MX2008010824A MX2008010824A MX2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A
Authority
MX
Mexico
Prior art keywords
iron
deferiprone
treat
methods
friedreich ataxia
Prior art date
Application number
MX2008010824A
Other languages
English (en)
Inventor
Michael Spino
Arnold Munnich
Ioav Cabantchik
Original Assignee
Arnold Munnich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnold Munnich filed Critical Arnold Munnich
Publication of MX2008010824A publication Critical patent/MX2008010824A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una cantidad terapéuticamente efectiva de deferiprona o deferasirox o sales fisiológicamente aceptables de los mismos para la prevención, estabilización, tratamiento, o reversión de enfermedad de FRDA inducida por hierro en pacientes que resulta de daño inducido por hierro mitocóndrico para reducir en forma preferente los depósitos de hierro en la mitocondria. Además para el tratamiento de otras condiciones que afectan el cerebro en donde un elemento clave en la generación de la patología resultante es el manejo intracelular inadecuado de hierro.
MX2008010824A 2006-02-22 2007-02-21 Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro. MX2008010824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22
PCT/CA2007/000252 WO2007095728A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Publications (1)

Publication Number Publication Date
MX2008010824A true MX2008010824A (es) 2009-06-08

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010824A MX2008010824A (es) 2006-02-22 2007-02-21 Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro.

Country Status (24)

Country Link
US (3) US20070197649A1 (es)
EP (1) EP1991225B1 (es)
JP (1) JP5730466B2 (es)
KR (1) KR20080104329A (es)
CN (1) CN101420954A (es)
AU (1) AU2007219009B2 (es)
BR (1) BRPI0708211A2 (es)
CA (1) CA2642778A1 (es)
DK (1) DK1991225T3 (es)
ES (1) ES2441065T3 (es)
IL (1) IL193598A (es)
MA (1) MA30266B1 (es)
MX (1) MX2008010824A (es)
MY (1) MY151412A (es)
NZ (1) NZ570730A (es)
PL (1) PL1991225T3 (es)
PT (1) PT1991225E (es)
RS (1) RS53225B (es)
RU (1) RU2008137604A (es)
SG (1) SG170020A1 (es)
SI (1) SI1991225T1 (es)
TN (1) TNSN08338A1 (es)
UA (1) UA95099C2 (es)
WO (1) WO2007095728A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991225B1 (en) * 2006-02-22 2013-11-06 Apotex Technologies Inc. The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
UY30986A1 (es) 2007-03-28 2008-09-02 Apotex Technologies Inc Derivados fluorinados de deferiprona
WO2009129592A1 (en) 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
EP2389179A4 (en) * 2009-01-26 2012-08-29 Michael Spino USE OF DEFERPRONE FOR THE TREATMENT AND PREVENTION OF IRON-RELATED EYE DISORDERS
MX2012000247A (es) 2009-07-03 2012-03-26 Apotex Technologies Inc Derivados fluorados de 3-hidroxipiridin-4-onas.
US20120157464A1 (en) 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2611457B1 (en) 2010-08-30 2014-03-19 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
US20200253945A1 (en) 2017-10-25 2020-08-13 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
EP1991225B1 (en) * 2006-02-22 2013-11-06 Apotex Technologies Inc. The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Also Published As

Publication number Publication date
TNSN08338A1 (en) 2009-12-29
US20130190365A1 (en) 2013-07-25
EP1991225A1 (en) 2008-11-19
AU2007219009A1 (en) 2007-08-30
CN101420954A (zh) 2009-04-29
IL193598A0 (en) 2009-08-03
UA95099C2 (ru) 2011-07-11
MY151412A (en) 2014-05-30
US20070197649A1 (en) 2007-08-23
SG170020A1 (en) 2011-04-29
JP5730466B2 (ja) 2015-06-10
MA30266B1 (fr) 2009-03-02
ES2441065T3 (es) 2014-01-31
RU2008137604A (ru) 2010-03-27
PT1991225E (pt) 2014-02-13
SI1991225T1 (sl) 2014-02-28
NZ570730A (en) 2013-05-31
DK1991225T3 (da) 2013-12-16
KR20080104329A (ko) 2008-12-02
EP1991225A4 (en) 2009-07-29
RS53225B (en) 2014-08-29
BRPI0708211A2 (pt) 2011-05-17
IL193598A (en) 2012-08-30
EP1991225B1 (en) 2013-11-06
CA2642778A1 (en) 2007-08-30
JP2009527506A (ja) 2009-07-30
US20090023784A1 (en) 2009-01-22
WO2007095728A1 (en) 2007-08-30
PL1991225T3 (pl) 2014-04-30
AU2007219009B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
MY151412A (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
MX2010004897A (es) Forma de dosificacion oralmente desintegrada.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
HK1130422A1 (en) A new use of deferiprone
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
NO20065662L (no) Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner
NZ595629A (en) Methods for preventing and/or treating lysosomal storage disorders
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
CL2009001600A1 (es) Composicion que comprende una fuente de dioxido de cloro, al menos 5 ppm de dioxido de cloro y no mas de 0,25 mg de aniones oxicloro por gramo de composiicon; util para aliviar infecciones de tejido en la cavidad oral.
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
MX2016001457A (es) Medicamentos terapeuticos de matriz extracelular endotelial corneal.
DE602006008186D1 (de) Neues imprägnierverfahren einer textiloberfläche
PL1680112T3 (pl) N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
NZ598754A (en) Therapeutic agent for anxiety disorders
CN205698180U (zh) 一种肩手一体式约束带
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
TN2010000249A1 (en) New medical use of 3-(2,2,2-trimethylhydrazinium ) propionate salts
CY1114714T1 (el) Η χρηση δεφεριπρονης και μεθοδοι για την θεραπεια και/ή προληψη της αταξιας friedreich που προκυπτει απο ενδοκυτταρικη κακη διαχειριση σιδηρου
NO20084999L (no) Fremgangsmate for behandling av arvelig hemokromatose
PH12018502446A1 (en) (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.

Legal Events

Date Code Title Description
FG Grant or registration